Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment.

failed to prove a statistically significant decrease in serum ALT levels (although demonstrating a decreasing trend) with neither improvement in fibrosis nor NAFLD scores with ARB therapy [ 118 ].

also in 47,180 other papers

On the contrary, a meta-analysis of several small studies suggested an association of rosiglitazone with MI and an overall trend toward death from CV causes [ 199 ].

also in 4,871 other papers